Clinical trials
Ocular Myasthenia Gravis clinical trials
Below are recruiting ocular myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 32 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07463521RecruitingPhase 3
Study of rozanolixizumab for ocular myasthenia gravis
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
Scottsdale, ArizonaAges 18 years+ - NCT07761026Recruiting
Living with myasthenia gravis: share your experience
This 10-year study collects information from people with myasthenia gravis to learn more about the condition and improve care. By sharing your experiences, you can help researchers understand what daily life is like and shape future treatments.
Framingham, MassachusettsAges 18 years+ - NCT07217587RecruitingPhase 3
Comparing two drugs for generalized myasthenia gravis
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Fullerton, CaliforniaAges 18–74 - NCT07717281Recruiting
Studying nerve-muscle organoids for refractory myasthenia gravis
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
MilanAges 18 years+ - NCT04182984Recruiting
Compare immunosuppressant medicines for eye-only myasthenia gravis
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
Xi'an, ShaanxiAges 18–75 - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05214612Recruiting
Predictors of outcomes in myasthenia gravis
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
AsyutAges 16 years+ - NCT05337891Recruiting
Evening vs morning nerve testing in myasthenia gravis
This study compares how well a nerve test works when done in the evening versus in the morning for people with myasthenia gravis. It may help doctors choose the best time to test nerve fatigue and better measure disease activity.
Krakow, Lesser Poland VoivodeshipAges 18–80 - NCT06342544RecruitingPhase 3
Steroids and rituximab to prevent myasthenia from spreading
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
BordeauxAges 18 years+ - NCT06617741Recruiting
Global Registry for Myasthenia Gravis Patients
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Westborough, MassachusettsAges 18 years+ - NCT06881173Recruiting
Traditional Chinese medicine for myasthenia gravis
This trial tests if a traditional Chinese herbal formula, Bu Zhong Yi Qi Tang, can help people with ocular myasthenia gravis. It combines the herbal treatment with standard Western medicine to see if it improves symptoms.
TaipeiAges 20 years+ - NCT07246564RecruitingPhase 4
Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
BeijingAges 18 years+ - NCT07249632RecruitingPhase 3
Study of Telitacicept for Eye Muscle Weakness from Myasthenia Gravis
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Beijing, Beijing MunicipalityAges 12–80 - NCT07250750RecruitingPhase 1/Phase 2
IM-101 for generalized and ocular myasthenia gravis
This study tests a new medicine called IM-101 in people with myasthenia gravis (MG), a muscle weakness condition. It aims to see if it can safely help manage symptoms.
Altamonte Springs, FloridaAges 18–74 - NCT07570589Recruiting
Tracking myasthenia gravis symptoms on rozanolixizumab treatment
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Nice, Alpes-maritimesAges 18 years+ - NCT07673744RecruitingPhase 2
Maintenance treatment for myasthenia gravis after efgartigimod
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
Colorado Springs, ColoradoAges 18 years+ - NCT06744920RecruitingPhase 3
New drug for generalized myasthenia gravis
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Phoenix, ArizonaAges 18–85 - NCT05868837RecruitingPhase 3
Rituximab for myasthenia gravis in people with moderate symptoms
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
RomaAges 18 years+ - NCT06704269RecruitingPhase 1/Phase 2
YTB323 for treatment-resistant generalized myasthenia gravis
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
Orange, CaliforniaAges 18–65 - NCT06463587RecruitingTeam says not enrollingPhase 3
Oral cladribine for generalized myasthenia gravis
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Phoenix, ArizonaAges 18 years+ - NCT07058298RecruitingEarly Phase 1
GC012F injection for hard-to-treat myasthenia gravis
This study tests an investigational drug called GC012F for people with generalized myasthenia gravis (gMG) that hasn't improved with standard treatments. The goal is to see if it can reduce symptoms and improve daily life.
Wuhan, HubeiAges 18–75 - NCT07215650RecruitingPhase 1
Cizutamig for generalized myasthenia gravis
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07413835Recruiting
Study of HN2302 for hard-to-treat myasthenia gravis
This trial tests a new medicine called HN2302 for people with generalized myasthenia gravis (MG) that hasn't improved with standard treatments. It aims to see if HN2302 is safe and helps reduce muscle weakness symptoms.
Xuzhou, JiangsuAges 18–80 - NCT06456580RecruitingPhase 3
Telitacicept for generalized myasthenia gravis
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Scottsdale, ArizonaAges 18 years+
Hear when a new Ocular Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ocular myasthenia gravis?
- Yes. Clin2 currently lists 32 recruiting ocular myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ocular myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ocular myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.